Effect of angiotensin II and small GTPase Ras signaling pathway inhibition on early renal changes in a murine model of obstructive nephropathy

Biomed Res Int. 2014:2014:124902. doi: 10.1155/2014/124902. Epub 2014 Jul 3.

Abstract

Tubulointerstitial fibrosis is a major feature of chronic kidney disease. Unilateral ureteral obstruction (UUO) in rodents leads to the development of renal tubulointerstitial fibrosis consistent with histopathological changes observed in advanced chronic kidney disease in humans. The purpose of this study was to assess the effect of inhibiting angiotensin II receptors or Ras activation on early renal fibrotic changes induced by UUO. Animals either received angiotensin II or underwent UUO. UUO animals received either losartan, atorvastatin, and farnesyl transferase inhibitor (FTI) L-744,832, or chaetomellic acid A (ChA). Levels of activated Ras, phospho-ERK1/2, phospho-Akt, fibronectin, and α-smooth muscle actin were subsequently quantified in renal tissue by ELISA, Western blot, and/or immunohistochemistry. Our results demonstrate that administration of angiotensin II induces activation of the small GTPase Ras/Erk/Akt signaling system, suggesting an involvement of angiotensin II in the early obstruction-induced activation of renal Ras. Furthermore, upstream inhibition of Ras signalling by blocking either angiotensin AT1 type receptor or by inhibiting Ras prenylation (atorvastatin, FTI o ChA) reduced the activation of the Ras/Erk/Akt signaling system and decreased the early fibrotic response in the obstructed kidney. This study points out that pharmacological inhibition of Ras activation may hold promise as a future strategy in the prevention of renal fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / administration & dosage*
  • Angiotensin II / metabolism
  • Animals
  • Atorvastatin
  • Disease Models, Animal
  • Fibrosis / drug therapy
  • Fibrosis / metabolism*
  • Fibrosis / physiopathology
  • Heptanoic Acids / administration & dosage
  • Humans
  • Kidney / metabolism*
  • Kidney Diseases / drug therapy
  • Kidney Diseases / metabolism*
  • Kidney Diseases / physiopathology
  • Mice
  • Monomeric GTP-Binding Proteins / antagonists & inhibitors
  • Monomeric GTP-Binding Proteins / metabolism*
  • Pyrroles / administration & dosage
  • Receptor, Angiotensin, Type 1 / metabolism
  • Signal Transduction / drug effects
  • Ureteral Obstruction / diet therapy
  • Ureteral Obstruction / metabolism
  • Ureteral Obstruction / physiopathology

Substances

  • Heptanoic Acids
  • Pyrroles
  • Receptor, Angiotensin, Type 1
  • Angiotensin II
  • Atorvastatin
  • Monomeric GTP-Binding Proteins